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Abstract
Background: Targeted disruption of the murine 3β-hydroxysterol-∆7-reductase gene (Dhcr7), an
animal model of Smith-Lemli-Opitz syndrome, leads to loss of cholesterol synthesis and neonatal
death that can be partially rescued by transgenic replacement of DHCR7 expression in brain during
embryogenesis. To gain further insight into the role of non-brain tissue cholesterol deficiency in
the pathophysiology, we tested whether the lethal phenotype could be abrogated by selective
transgenic complementation with DHCR7 expression in the liver.
Results:  We generated mice that carried a liver-specific human DHCR7  transgene whose
expression was driven by the human apolipoprotein E (ApoE) promoter and its associated liver-
specific enhancer. These mice were then crossed with Dhcr7+/- mutants to generate Dhcr7-/- mice
bearing a human DHCR7 transgene. Robust hepatic transgene expression resulted in significant
improvement of cholesterol homeostasis with cholesterol concentrations increasing to 80~90 %
of normal levels in liver and lung. Significantly, cholesterol deficiency in brain was not altered.
Although late gestational lung sacculation defect reported previously was significantly improved,
there was no parallel increase in postnatal survival in the transgenic mutant mice.
Conclusion:  The reconstitution of DHCR7 function selectively in liver induced a significant
improvement of cholesterol homeostasis in non-brain tissues, but failed to rescue the neonatal
lethality of Dhcr7 null mice. These results provided further evidence that CNS defects caused by
Dhcr7 null likely play a major role in the lethal pathogenesis of Dhcr7-/- mice, with the peripheral
organs contributing the morbidity.
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Background
The role of cholesterol in embryonic development is an
important question in biology, with significant ramifica-
tions for human disease [1,2]. Defects in post-squalene
cholesterol biosynthesis, such as in Smith-Lemli-Opitz
syndrome (SLOS, MIM 270400) or desmosterolosis (MIM
603398), disrupt the synthesis of cholesterol and cause a
variety of severe developmental abnormalities [3-8]. SLOS
is a complex inborn error of cholesterol biosynthesis
caused by mutations of the 3β-hydroxysterol-∆7 reductase
gene (DHCR7) [9-11]. The lack of Dhcr7 expression in
mouse mimics the early postnatal lethality observed in
severely affected individuals (those with the condition
formerly referred to as SLOS type II). The biological
changes in development caused by disruption of normal
cholesterol biosynthesis that result in this early postnatal
lethality remain obscure. As a genetic model for under-
standing of the SLOS in human, mice lacking Dhcr7 pro-
vide a useful model to determine which affected tissues
are critically responsible for the lethality and which ones
may contribute to the morbidity.
One cause of early postnatal death in the Dhcr7 null ani-
mals appears to be associated with anoxia due to diffuse
atelectasis of the late gestational lungs [12-14], which may
cause immature formation of gas-exchange unit and sub-
sequent respiratory insufficiency after birth [2,14]. There-
fore, lung involvement seems to be a cause of neonatal
death in Dhcr7 null mouse model. However, there is still
uncertainty regarding the mechanism(s) responsible for
the late gestational lung hypoplasia caused by the loss of
endogenous cholesterol biosynthesis in Dhcr7-/- mice. As
with any biological aspect of a generalized cholesterol
deficiency, the pathophysiology is likely to be complex
and multi-factorial. It remains unclear whether the
delayed lung maturation is caused by a developmental
defect intrinsic to lung or whether it represents a systemic
abnormality, especially of the central nervous system
(CNS), because of impaired cholesterol homeostasis dur-
ing embryogenesis. A different variety of developmental
abnormalities in brain have also been noted in both
human patients and, to some extent, in Dhcr7-deficient
animal models. In this regard, we have also recently dem-
onstrated that Dhcr7-/- mice can be partially rescued from
neonatal death by a low level restoration of DHCR7
expression in brain, indicating that neuropathophysiol-
ogy is one cause of their neonatal lethality [15].
In attempting to rescue Dhcr7-deficient mice, we felt that
it was necessary to consider the liver because that organ is
a major source of cholesterol for most developing organs,
except for brain [4,16-19]. Thus, we hypothesized that res-
toration of normal cholesterol synthesis in the liver might
be able to abrogate the lethality. In the current study, we
asked whether the specific reconstitution of DHCR7
expression in liver would alleviate the cholesterol defi-
ciency and afford protection from early postnatal death in
Dhcr7 null mice. Our results suggest that, although
expression of DHCR7 in liver alone during development
induced a significant improvement in cholesterol home-
ostasis in non-brain tissues and promoted lung matura-
tion, it failed to rescue the neonatal lethality. These results
provided further evidence that CNS defects caused by
Dhcr7 null likely play a major role in the lethal pathogen-
esis of Dhcr7-/- mice, with the peripheral organs contribut-
ing the morbidity.
Results
Characterization of TgDHCR7 lines
Three mice (one female and two males), referred as to
TgDHCR7-1, TgDHCR7-2 and TgDHCR7-3, respectively
(Fig. 1), were identified as transgenic on the basis of PCR
and Southern blot analyses of tail samples of genomic
DNA. Multiple tissues were collected from N2 transgenic
progeny from the founder mice crossed with C57Bl/6J at
postnatal day (P) 10 and analyzed for transgene expres-
sion by RT-PCR and immunoblotting. Both TgDHCR7-2
and TgDHCR7-3 transgenic lines expressed human
DHCR7 mRNA robustly in the postnatal livers, but not in
the other tissues (Fig. 2A,C) and western blotting analyses
showed expression of HA-tagged protein (Fig. 2D).
TgDHCR7 mRNA transcript was detected in transgenic
liver at E11.5 (the earliest we could dissect liver tissue) by
RT-PCR determination (Fig. 2B) and was quantitatively ~5
fold higher than endogenous murine Dhcr7 mRNA in the
transgenic liver at E16.5 as judged by real-time PCR (Fig.
2C). Immunofluorescence staining with anti-HA anti-
body showed that TgDHCR7 was highly expressed in
hepatocytes in liver sections, but such signal was not
detectable in control liver (Fig. 2E). Further studies there-
fore utilized these two lines, which were backcrossed with
C57Bl/6J for 4 to 5 generations. Since no differences
between either line were identified, these lines were used
interchangeably.
Sterol metabolic profile of TgDHCR7/Dhcr7-/- mice
To determine the physiological consequences of selective
restoration of DHCR7 expression in liver, we bred the
transgene onto Dhcr7 null background (see Methods).
Steady-state sterol levels in P0-P1 neonates were obtained
by sacrificing the litters from the initial crosses, tissues and
plasma harvested and genotypes performed on DNA
extracted from tails. Cholesterol levels in Dhcr7-/-Tg+
plasma (pooled plasma from 9 animals, pooling per-
formed by combining plasma from 3 pups) were signifi-
cantly improved compared to non-transgenic Dhcr7-null
plasma (Fig. 3A), plasma 7-dehydrocholesterol (7DHC)
and 8-dehydrocholesterol (8DHC) sterols were reduced
and the percentage precursor levels significantly decreased
(cf. Fig. 3B and 3C). Thus the expression of the transgeneBMC Developmental Biology 2007, 7:27 http://www.biomedcentral.com/1471-213X/7/27
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in the liver led to improvements in the plasma sterol pro-
files.
Liver sterol profiles in Dhcr7-/-Tg+ pups showed that tissue
cholesterol was restored to almost wild-type liver level
and precursor levels were reduced by ~70% suggesting the
liver defect was not fully restored (Fig. 4). It is important
to note that whole liver tissue in the embryonic and neo-
natal mouse also contains substantial non-hepatic (pri-
marily hematopoetic) cells.
Remarkably, tissue sterol levels in Dhcr7-/-Tg+ lung also
showed a dramatic restoration of cholesterol (Fig. 5A).
Precursor sterol profiles were also significantly improved,
and were similar in profile to that observed for the liver
(Fig. 5B and 5C), though the reductions were more mod-
est (~40%). In contrast, there was almost no change in the
sterol profiles in brain from knockout animals that
expressed the transgene in the liver (Fig. 6). Although cho-
lesterol levels in Dhcr7-/-Tg+ brains were statistically
higher than non-transgenic mutant brains (Fig 6A), this
Generation of TgDHCR7 mice Figure 1
Generation of TgDHCR7 mice. Panel A shows a cartoon of the transgene construct used for microinjection. The human 
Apo E promoter containing non-coding exon 1 (E1), intron 1 and part of non-coding exon 2 (E2) was fused to a N-terminal 
3HA tagged human DHCR7 cDNA containing intron 5, followed by a human Apo E poly A addition site (pA), and a liver 
enhancer element. Panel B shows the results of the Southern blot analysis of Bam HI-digested DNA from the three TgDHCR7 
(Tg) founder mice (lane 3, 4 and 5). Lane 1 is λ-Hind III DNA marker and lane 2 contains DNA from a Tg negative control ani-
mal. The arrowhead points to the expected size bands for TgDHCR7 (2.3 kb). Additional bands (asterisks) indicate the inte-
grated transgene that has undergone some deletions or rearrangements.
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Characterization of TgDHCR7 transgene expression Figure 2
Characterization of TgDHCR7 transgene expression. Panel A shows the tissue distribution of TgDHCR7 transgene 
mRNA as determined by RT-PCR. Amplification was performed with primers bounding the intron in the transgene. Note that 
expression was readily detectable on the liver tissues only. Panel B shows the profile of TgDHCR7 transgene expression dur-
ing embryonic liver development, determined by RT-PCR. The samples were taken from embryonic days as indicated. Robust 
expression was detectable in liver tissue as early as E11.5. Panel C shows quantitation of transgene mRNA expression 
(TgDHCR7) relative to endogenous Dhcr7 (endo-Dhcr7) in liver samples by real-time RT-PCR. The transgene message was 
almost 5-fold greater than endogenous Dhcr7 message. The mean ± SD of Ct values of Tg-DHCR7 and endogenous Dhcr7 are 
shown in chart. Panel D shows protein expression of transgenic HA-tagged DHCR7 from the multiple tissues of TgDHCR7 
(Tg) positive (+) and Tg negative (-) control mice. Membrane and cytosolic fractions from the multiple tissues of TgDHCR7-2 
and TgDHCR7-3 positive animals (liver 1 and 2 respectively, lanes 3 and 4) and the livers of Tg negative control mice (liver 3 and 
4, lanes 5 and 6) were prepared for immunoblotting analyses as described in Methods. The upper panel shows western blotting 
data using monoclonal anti-HA antibody (arrow denotes DHCR7 ~43 kDa). The asterisk at 48 KDa indicates immunoreactivity 
to IgG heavy chain in the samples. Middle and lower panels are immunoblots for calnexin (an ER membrane marker) and cave-
olin-1 (cav1, a plasma membrane marker), respectively, as controls. Panel E shows immunohistochemical staining with anti-
HA antibody (left panel) and phase-contrast (middle panel) images of transgenic liver sections. No signal was detected with the 
antibody in control liver (right panel). T indicates liver portal triad.
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Sterol analyses of liver tissues from wild-type, knockout and knockout- transgenic pups Figure 4
Sterol analyses of liver tissues from wild-type, knockout and knockout- transgenic pups. Panel A shows that the 
significant cholesterol deficiency in Dhcr7-/-Tg- neonates (1.0 ± 0.53 mg/g tissue, P < 0.001 cf to WT) was restored to normal by 
the transgene expression (2.03 ± 0.64 mg/g tissue) and was not statistically different from WT livers (2.48 ± 0.38 mg/g tissue). 
Cholesterol level in livers from Dhcr7+/+Tg+ littermates was 2.45 ± 0.42 mg/g tissue (data not shown). Massive accumulation of 
7/8DHC in livers of Dhcr7-/-Tg- neonates (1.46 ± 0.45 mg/g tissue, Panel B), was significantly decreased to 0.48 ± 0.33 mg/g tis-
sue in Dhcr7-/-Tg+ livers and only trace levels in livers of WT mice were detected (0.01 ± 0.02 mg/g tissue). The percent of 
sterol precursors in total sterols was also significantly improved in Dhcr7-/-Tg+ livers (19 ± 13 %), compared to Dhcr7-/-Tg- mice 
(59 ± 12 %, p < 0.001, Panel C). No significant difference (p > 0.05) was found in total sterol levels (mg/g tissue) among the 
three groups (2.49 ± 0.49 in WT, 2.43 ± 0.53in Dhcr7-/-Tg- and 2.51 ± 0.51in Dhcr7-/-Tg+). Results are expressed as mean ± SD.
,IVER
" ! #
Pooled plasma sterol analyses from neonatal pups Figure 3
Pooled plasma sterol analyses from neonatal pups. Sterol levels in three pooled plasma samples (9 pups per genotype, 
pooled by combining samples from 3 pups) collected from animals of each genotype. Plasma cholesterol levels (mg/dl) in WT, 
Dhcr7-/-Tg- and Dhcr7-/-Tg+ neonates were 71.7 ± 5.68, 13.5 ± 1.3 and 33.7 ± 10.4, respectively (Panel A). 7/8DHC (mg/dl) 
was 0.12 ± 0.04 in WT plasma and a massive accumulation of 7/8DHC was found in Dhcr7-/-Tg- (10.5 ± 1.8). 7/8DHC level in 
Dhcr7-/-Tg+ plasma (5.7 ± 0.7) was ~50 % of Dhcr7-/-Tg- level, but still ~47-fold higher than WT level (Panel B). The percent of 
sterol precursors appeared to be dramatically reduced in Dhcr7-/-Tg+ plasma (19.5 ± 7.6 %), compared to Dhcr7-/-Tg- mice (77.6 
± 13.6 %) (Panel C). And total sterols (mg/dl) in WT, Dhcr7-/-Tg- and Dhcr7-/-Tg+ neonates were 71.8 ± 5.67, 23.9 ± 2.62 and 
39.3 ± 10.1, respectively. Results are expressed as mean ± SD.
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increase was minimal and the brains showed significant
cholesterol deficiency. Additionally, the presence of the
transgene had no effect on either the total 7/8DHC pre-
cursors (Fig. 6B) or the different species of precursors (Fig.
6C). We speculate that the small increase in brain choles-
terol seen in the Dhcr7-/-Tg+ may reflect the contamina-
tion of the brain by the increased cholesterol in the blood.
Collectively, these data indicated that selective reconstitu-
tion of DHCR7 expression in liver improved significantly
cholesterol homeostasis in liver, lung and circulation of
Dhcr7 null animals during embryogenesis, but did not
affect metabolism in the brain.
Late gestational lung development in Dhcr7-/-Tg+ mice
Loss of Dhcr7 in mice leads to subtle, but reproducible
defects in lung development; all knockout pups show
impaired saccular and capillary growth development
caused by developmental arrest at the very last stages of
lung development [14]. The primary cell defect seems to
be a failure of terminal differentiation of type 1 alveolar
epithelial cells (AECs). Since the hepatic transgene expres-
sion led to an increase in significant amounts of lung tis-
sue cholesterol, we examined for effects on lung
phenotype in near term embryos (E19.5) that were wild-
type (WT), Dhcr7-/-Tg+ and Dhcr7-/-Tg-. At this stage, the
lungs of WT mice showed normal sacculation (Fig. 7A)
with formation of pre-alveoli that have thin septa (Fig.
7B). In contrast, lungs from Dhcr7 null mice (Fig. 7E and
7F) showed the lack of saccular formation, with failure to
thin out the pre-alveolar septae and development of sac
spaces, in keeping with our previous findings. Interest-
ingly, the lungs from Dhcr7 null mice expressing DHCR7
in the liver showed an intermediate phenotype, with
improved sac space formation and thinning of the pre-
alveolar septae (Fig. 7C and 7D). Analyses of the sac space
volumes showed that transgenic KO lungs had an increase
in terminal sac spaces, compared to non-transgenic
mutant lungs (Fig. 7G). Immunohistochemical character-
ization of these lungs confirmed this histological
improvement (Fig. 8). We had previously shown abnor-
mal T1-α, PECAM-1 and caveolin-1 staining patterns in
Dhcr7 null lungs, with preserved surfactant protein stain-
ing. The transgene expression led to an improvement in
all of these staining patterns (Fig. 8, cf. panels B, E, H and
K with C, F, I and L), suggesting that transgenic-induced
improvement of cholesterol homeostasis in non-brain tis-
sues normalized the architecture of the distal lung saccu-
lation.
Postnatal survivability of Dhcr7-/-Tg+ mice
Since all of the Dhcr7 null pups die within 24 h of birth
(usually within 14 h), we wished to see if the improve-
ment in the cholesterol by liver transgene expression
improved survival. One hundred and ninety-six pups
from  Dhcr7+/-Tg+ females bred with Dhcr7+/-Tg+ males
Sterol analyses of lung tissues from wild-type, knockout and knockout- transgenic pups Figure 5
Sterol analyses of lung tissues from wild-type, knockout and knockout- transgenic pups. Panel A shows that cho-
lesterol level in lung tissues was restored to normal by the liver transgene expression (to 2.51 ± 0.71 mg/g tissue) in Dhcr7-/-
Tg+ lungs and was not statistically different from WT lungs (of 3.06 ± 0.40 mg/g tissue), while the non-transgenic-KO lungs 
exhibited significant cholesterol deficiency (1.25 ± 0.44 mg/g tissue). Cholesterol level in lungs from Dhcr7+/+Tg+ littermates 
was 3.18 ± 0.54 mg/g tissue (data not shown). Panel B shows that this also led to a fall in precursor sterols (0.88 ± 0.30 mg/g 
tissue in Dhcr7-/-Tg+ cf 1.39 ± 0.22 mg/g tissue in Dhcr7-/-Tg-), with a significant fall in the percentage of precursor sterol in the 
lung tissues of the transgenic-KO mice (25 ± 8 %, compared to 53 ± 5 % in Dhcr7-/-Tg- mice, p < 0.001, Panel C). There was 
no significant difference (p > 0.05) in total sterols among the three groups (lung total sterols mg/g tissue: 3.10 ± 0.40 in WT, 
2.64 ± 0.62 in Dhcr7-/-Tg- and 3.59 ± 1.08 in Dhcr7-/-Tg+, data not shown). Error bars represent mean ± SD.
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were scored for viability. The survival rates, defined as
pups remaining alive beyond 24 h after birth, are summa-
rized in Table 1. When observed at birth, in general, pups
that appeared bluish, hypotonic, breathed with difficulty,
demonstrated no suckling activity, became dehydrated,
and died within 24 h after birth were genotyped to be
non-transgenic Dhcr7-/-, all features of being Dhcr7 null,
as described previously [14]. Of the Dhcr7-/-Tg+ pups that
were relatively pink within minutes after being born,
twelve of 28 (42.8%) from TgDHCR7 line-2 and 8 of 14
(57.1%) from TgDHCR7 line-3 survived the first postnatal
day, but died within 48 h after birth. Dhcr7-/-Tg+ pups
were also observed to show some hypotonia and poor
suckling reflexes similar to Dhcr7-/-Tg- pups. The remain-
ing pups were sacrificed after 2 days to confirm that none
of the survivors to this point were null for Dhcr7. There-
fore, liver-specific restoration of cholesterol biosynthesis
improved survival to up to 48 hours, but all Dhcr7 null
pups still died. Thus, despite the hepatic, blood and non-
brain tissue cholesterol and developmental improve-
ments by hepatic transgene expression, lethality was min-
imally delayed.
Association of cholesterol and 7/8DHC with lipid 
membranes
Participation in the formation and function of membrane
lipid microdomains (rafts) is an important function of
cholesterol [20,21]. To address whether the transgene
expression led to alterations of sterol distributions
between raft and non-raft membrane fractions, we frac-
tionated membranes from lung tissues from these three
genotypes. To isolate detergent-resistant membranes
(DRMs or rafts), Triton X-100 (TX) extracted postnuclear
supernatants prepared from wild-type (WT), Dhcr7-/-Tg-
and Dhcr7-/-Tg+  neonatal lungs were differentially frac-
tionated in discontinuous sucrose gradients [22] and ana-
lyzed. Figure 9A showed protein and organic-phosphate
distribution in TX sucrose gradients; there were no differ-
ences between any of the genotypes. Cholesterol and pre-
cursor sterols were analyzed from gradient fractions by
GC-MS (Fig. 9B–D). In WT lungs, cholesterol was detected
as the only major sterol (Fig. 9B, open circles), 7/8DHC
levels were undetectable (Fig. 9C, open circles), and
showed a bimodal profile, with one sharp peak corre-
sponding to the raft fractions (fractions 2–4), the second
peak found in high-density non-raft fractions (fractions
8~11, Fig. 9B), in keeping with previous reports using
detergent or detergent-free methods [23-26]. In Dhcr7-/-
Tg- lungs, sterols composed of a mixture of 7/8DHC and
cholesterol, also exhibited bimodal profiles, and 7/8DHC
constituted the major sterol in both raft and non-raft frac-
tions (Fig. 9B and 9C, filled circles). In Dhcr7-/-Tg+ lungs,
although, in both raft and non-raft fractions, cholesterol
was dramatically increased, considerable amount of 7/
8DHC was still detected (Fig. 9B and 9C, filled dia-
monds). Total sterol levels (Fig. 9D) were similar in all
three groups. Quantitative analyses of sterol content in
rafts (n = 3, pooled fractions 2~4) and non-rafts (pooled
fractions 8~11) are shown in Fig. 9E and 9F, respectively.
Significantly increased cholesterol, ~70 % of WT levels,
was observed in rafts from Dhcr7-/-Tg+ lungs, compared to
Dhcr7-/-Tg- lungs. However, raft cholesterol in Dhcr7-/-Tg+
Sterol analyses in brain tissues from wild-type, knockout and knockout- transgenic pups Figure 6
Sterol analyses in brain tissues from wild-type, knockout and knockout- transgenic pups. A slightly elevated cho-
lesterol level was found in Dhcr7-/-Tg+ brains, compared to Dhcr7-/-Tg- brains (0.58 ± 0.03 mg/g brain tissue in Dhcr7-/-Tg+ vs. 
0.47 ± 0.06 mg/g brain tissue in Dhcr7-/-Tg-, p < 0.05, see Text for discussion) (Panel A). However, there were no significant 
alterations of 7/8DHC levels (3.42 ± 0.53 mg/g tissue in Dhcr7-/-Tg+ vs. 3.01 ± 0.38 mg/g tissue in Dhcr7-/-Tg-, p > 0.05) (Panel 
B), or of the ratios of different precursors in Dhcr7-/-Tg+ (89 ± 1 %), compared to Dhcr7-/-Tg- brains (91 ± 2 %, p > 0.05) 
(Panel C). No significant difference (p > 0.05) was found in brain total sterol levels among three groups (mg/g tissue: 4.63 ± 
0.46 in WT, 5.05 ± 0.68 in Dhcr7-/-Tg- and 5.33 ± 0.66 in Dhcr7-/-Tg+, data not shown). Results are expressed as mean ± SD.
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Lung histology in wild-type, knockout and knockout-transgenic embryos Figure 7
Lung histology in wild-type, knockout and knockout-transgenic embryos. Histological sections of lungs from WT, 
Dhcr7-/-Tg+ and Dhcr7-/-Tg- at term (E19.5) were stained with hematoxylin/eosin (H & E) and photographed. WT lung depicts 
late saccular phase of lung development (Panels A and B). Considerable elongation of the secondary crests (arrows) and a 
more thinned mesenchyme are evident throughout the WT lung. Dhcr7-/-Tg- lung showed less distal saccular structures, had 
thick-walled mesenchyme and septation appeared not to be progressing, with undeveloped epithelial tubular structures 
(arrowheads) throughout the lung fields (Panels E and F). Although these changes are also present in the lungs from trans-
genic-KO lungs, less severe hypoplasic lung phenotypes are evident in Tg+ mutant mice (Panels C and D, arrows show sec-
ondary crests), compared to WT and Dhcr7-/-Tg- animals. Panel G shows the morphometric analyses of lung terminal sac 
spaces in lungs of WT, Dhcr7-/-Tg+ and Dhcr7-/-Tg- at E19.5. Results are expressed as mean ± SD. Labels: a, pre-alveolar spaces; 
br, bronchiole.
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Immunostaining of selected marker proteins expressed in distal lung Figure 8
Immunostaining of selected marker proteins expressed in distal lung. Lung sections at E19.5 from WT control (Pan-
els A, D, G and J), Dhcr7-/-Tg+ (Panels B, E, H and K) and Dhcr7-/-Tg- (Panels C, F, I and L) were immunostained with 
antibodies against T1-α, SP-C, caveolin-1 (cav-1), and PECAM-1, respectively. Immunostaining for SP-C shows relative similar 
patterns and numbers of positive cells (brown dots, indicated by arrowheads) in WT control (Panel D), Dhcr7-/-Tg+ (Panel E) 
and Dhcr7-/-Tg- (Panel F) lungs. T1-α expression in WT lung (Panel A) is confined to flattened cells lining the pre-alveolar spaces 
(arrow). A decreased pattern of T1-α expression, especially in undeveloped epithelial tubules (arrowheads), is clearly evident 
in Dhcr7-/-Tg- lung (Panel C). Both cav-1 (Panel G) and PECAM-1 (Panel J) staining demonstrate an extensive vascular network 
in the well developed saccules in WT lung, however, delayed vascular development was observed in Dhcr7-/-Tg- lung (Panel I 
and L). Note that T1-α, cav-1 and PECAM-1 expressive patterns in Dhcr7-/-Tg+ lung (Panels B, H and K, respectively) appear in 
the middle between WT and Dhcr7-/-Tg- lungs. Labels: a, pre-alveolar spaces; br, bronchiole.
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lung was still significantly lower than that in WT lungs.
Raft 7/8DHC level was significantly reduced, but a consid-
erable accumulation was evident in Dhcr7-/-Tg+  lungs.
Interestingly, although non-raft cholesterol levels in
Dhcr7-/-Tg+ lungs were comparable to WT, there was no
significant decrease of non-raft 7/8DHC levels in Dhcr7-/-
Tg+ lungs, compared to Dhcr7-/-Tg- lungs. These data sug-
gest that precursor sterols can be found in raft fractions,
but that total sterol distributions appear to be similar in
WT and knockout lungs.
Discussion
Severe cholesterol deficiency, caused by the intentional
genetic ablation of Dhcr7 in the mouse, has proven to be
incompatible with perinatal life and is associated with res-
piratory insufficiency after birth [12-14]. However, Dhcr7
null pups also exhibit other defects that indicate other
organs/systems are also disrupted by absence of normal
cholesterol synthesis. A key question is therefore which of
these organs (whose lack of normal development) leads
to the neonatal lethality. The hypoxia and abnormal lung
phenotype would suggest this could be a major defect,
though it is also possible that a failure to integrate respira-
tion at the CNS level could be equally important. In our
preliminary effort to restore DHCR7 activity in the CNS,
we reported a stochastic rescue of pups up to 3 weeks
beyond birth, despite almost no increase in brain choles-
terol, or fall in precursor sterol concentrations [15]. At the
same time, we had also embarked upon restoration of
cholesterol synthesis in peripheral (non-brain) tissues to
see if this could abrogate the lethality. We report herein
the effects of restoration of cholesterol synthesis in the
developing liver, an organ that can circulate lipoproteins
and cholesterol at a very embryonic age.
Selective reconstitution of liver cholesterol biosynthesis
resulted in significant improvement of cholesterol home-
ostasis in all of the tissues examined in Dhcr7 null mice
with the exception of the brain, confirming the embryonic
liver's ability to supply cholesterol to peripheral tissues
and the inability of cholesterol in the circulation to cross
the blood-brain barrier. Cholesterol was detectable in
liver and lung of non-transgenic Dhcr7-null term pups at
~40% of normal levels, which represents maternal trans-
fer of this cholesterol and confirmed previous findings
[27]. Cholesterol levels in both liver and lungs of trans-
genic Dhcr7-null term pups increased to ~80% of WT
level (and statistically not different from WT levels), indi-
cating robust transgenic liver expression of DHCR7 led to
adequate delivery of endogenously synthesized choles-
terol to the lungs (presumably via lipoprotein-mediated
transfer). The alleviation of the non-brain tissue choles-
terol deficit in the transgenic Dhc7-null embryos led to
improvement in the lung development, but not complete
restoration of normal development.
Although our data support the conclusion that the lung
defects may not be the major reason for the neonatal mor-
tality, some caveats need to be mentioned. Despite signif-
icantly increased cholesterol in the lung, the sterol
precursors were reduced by ~40% and not completely
suppressed. Sterol precursors have been demonstrated to
be part of plasma membranes and their presence may
have significant implications in altering membrane sign-
aling, by altering raft formation and functions [28-33]. In
this study, membrane sterol distributions were further
investigated and compared between transgenic and non-
transgenic  Dhcr7-/-  lungs. Adapting an established
method, lipid-rafts and non-rafts were prepared by
sucrose gradient fractionation of Triton X100 extracted tis-
sue homogenates [22]. Bimodal profiles of cholesterol
and 7/8DHC in sucrose gradient fractions were found,
with first peak enriched in "raft" fractions and the second
peak found in non-raft fractions. Thus, the bimodal pro-
file may represent sterol portions distributed in lipid-raft
microdomains and subcellular membranes [23,25]. As
expected, although significant restoration of cholesterol
level, a considerable amount of 7/8DHC was still accumu-
Table 1: Survival beyond 24 h of birth in transgenic and non transgenic Dhcr7-/pups
Genotype* n Survival** Survival rate (%)
<24 h >24 h
TgDHCR7 line 2 WT 29 0 29 100
Dhcr7+/- 57 0 57 100
Dhcr7-/-Tg- 55 0 0
Dhcr7-/-Tg+ 28 16 12 42.8
TgDHCR7 line 3 WT 19 0 19 100
Dhcr7+/- 40 0 40 100
Dhcr7-/-Tg- 44 0 0
Dhcr7-/-Tg+ 14 6 8 57.1
* Tg positive and negative pups are included in WT and Dhcr7+/- groups. **Survival is defined as being alive beyond 24 hours after being born.BMC Developmental Biology 2007, 7:27 http://www.biomedcentral.com/1471-213X/7/27
Page 11 of 15
(page number not for citation purposes)
Characterization of sterol distributions in lipid membranes in wild-type, knockout and knockout-transgenic lungs Figure 9
Characterization of sterol distributions in lipid membranes in wild-type, knockout and knockout-transgenic 
lungs. Panel A shows the distributions of protein and phosphate in membrane fractions from sucrose gradients of WT (open 
circles), Dhcr7-/-Tg- (closed circles) and Dhcr7-/-Tg+ (filled diamonds) lungs. Fractions 2–4 represent buoyant fractions indicative 
of rafts. Panel B shows the distribution of cholesterol, Panel C that for precursor sterols 7/8DHC and Panel D that for total 
sterol (symbols as above). While the total sterol profiles are indistinguishable (Panel D), precursor sterols are increased and 
cholesterol decreased in the lungs from knockout animals (Panels B and C). Note that the distribution of precursor sterols is 
also bimodal in knockout lungs and the improvement of the cholesterol/precursor ratio by the Tg status. Quantitative compar-
ison of sterol composition in rafts (fraction 2~4) and non-rafts (fractions 8~11) in WT, Dhcr7-/-Tg- and Dhcr7-/-Tg+ lungs was 
performed on three separate samples and data were normalized to organic-phosphate, Panel E and F. Results are expressed as 
mean ± SD. Genotypes are as indicated. See Results for discussion.BMC Developmental Biology 2007, 7:27 http://www.biomedcentral.com/1471-213X/7/27
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lated in the rafts of transgenic Dhcr7-/- lungs. Thus one
mechanistic possibility is that raft-mediated signaling
may be important for the terminal differentiation of Type
1 AECs (and capillary endothelial cells), and that this
defect was not fully complemented by increasing the
uptake of cholesterol from exogenous sources and thus
the lung-associated mortality was not altered. The defect
in cholesterol biosynthesis in the lungs will continue to
lead to generation of precursor sterols and since these ster-
ols are readily incorporated into plasma membranes, res-
toration of normal raft function may require direct
restoration of Dhcr7 activity [30-34].
Another possibility is that pulmonary surfactant altera-
tion may also play a role in the Dhcr7-deficient lung phe-
notype, since pulmonary surfactant, the lipid-protein
material that stabilizes the respiratory surface of the lung,
has been described to function as lipid microdomains.
However, we have reported that expression of surfactant
proteins, both at the mRNA and at the immunohisto-
chemical level, was indistinguishable between Dhcr7-null
and wild-type embryos [14]. Cholesterol concentration, a
critical parameter in modulating the lateral structure of
pulmonary surfactant membranes as evidenced by in-
vitro studies, may provide a structural scaffold for sur-
factant proteins to act at appropriate local densities and
lipid composition [35]. A difference in the condensing
ability of cholesterol and 7DHC in monolayer films of
dipalmitoyl phosphatidylcholine (DPPC), a major sur-
factant phospholipid, and their different abilities to form
lateral domains with DPPC has also been demonstrated
[36]. Sterols can induce upregulation of phosphatidylcho-
line synthesis in cultured fibroblasts and this process is
affected by the double-bond position in the sterol tetracy-
clic ring structure [37]. Therefore, markedly reduced cho-
lesterol content and the massive accumulation of
precursor sterols, such as 7/8DHC, may affect lung devel-
opmental at late gestational stages by the modulation of
surfactant properties, even if surfactant protein expression
is normal. However, restoration of DHCR7 activity in the
lung using a transgene that expressed DHCR7 activity did
not rescue this lethality (Yu and Patel, unpublished obser-
vations). Additionally, our previous brain-specific
DHCR7 transgenic expression studies showed that some
rescue was possible, even though lung sterol profiles were
not altered [15]. Thus, while lung defects remain a con-
tributory factor for this lethality, we contend that a defect
in the CNS is the major reason why SLOS pups die soon
after birth.
Some positive aspects should also be highlighted. Since
the only cells that could synthesize cholesterol were the
hepatocytes in the developing liver, yet there was robust
restoration of cholesterol in the peripheral organs, this
further confirms previous studies on the importance of
lipoprotein-mediated liver-derived cholesterol delivery to
these organs [18]. Additionally, this study also confirms
the now well-established physiological observation that
the blood-brain barrier is an absolute barrier for entry of
pre-formed cholesterol into the brain and it is operational
as early as E10 in the mouse [27].
One curious finding confounding the above interpreta-
tions is that, although cholesterol levels in the transgenic
Dhcr7-null livers increased to almost WT levels, the pre-
cursor levels in the liver were reduced by only 70 %,
despite an almost 5-fold increase in the relative expression
of the transgene in the liver. Our explanation for this is
that the fetal and neonatal mouse liver contains more
than hepatocytes, with a significant amount of hematopo-
etic activity that persists beyond birth. The ApoE promoter
chosen will only result in robust hepatic-specific expres-
sion. Since total dissected organ tissue sterols are meas-
ured, we presume that the precursor accumulations are
therefore primarily in these non-hepatic cells and not
hepatocytes. If so, it also suggests that close proximity of
the hepatocytes and hematopoetic stem cells does not
result in complementation or clearance of the precursor
sterols from the latter. Thus, while cholesterol can be effi-
ciently delivered to the various tissues readily via the lipo-
protein-mediated pathways, removal of the precursor
sterols back to the liver may not be as efficient.
Conclusion
Restoration of liver cholesterol synthesis is an efficient
method to restore peripheral tissue cholesterol in Dhcr7-
null embryos, and this can lead to an improvement in the
lung developmental defects reported previously and a
minimal improvement in the neonatal lethality was also
observed. However, this strategy does not affect the sterol
defect in the CNS and this organ may be critically respon-
sible for the neonatal lethality.
Methods
Generation of transgenic mice expressing human 
DHCR7specifically in liver
To generate transgenic mice expressing DHCR7 in the
liver, we used a pLIV-LE6 vector that contains the consti-
tutive human Apo E gene promoter and its hepatic control
region (a gift from John Taylor, J. David Gladstone Insti-
tutes, San Francisco). N-terminal 3 hemagglutinin (HA)
epitope tagged human DHCR7 cDNA with intron 5 (3HA-
DHCR7in5) was generated by routine PCR insertion
method. The transgenic plasmid (pLiv-11-3HA-
DHCR7in5) was generated by cloning 3HA-DHCR7in5
fragment encoding the open reading frame of human
DHCR7 into Mlu I-Cla I sites of pLIV-LE6. The 6-kb Not I-
Spe I fragment of pLiv-11-3HA-DHCR7in5 (Fig. 1) was
then isolated and injected into fertilized eggs (C57Bl ×
FVB/N) to generate transgenic mice by Medical UniversityBMC Developmental Biology 2007, 7:27 http://www.biomedcentral.com/1471-213X/7/27
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of South Carolina Transgenic Core facility. Transgene-spe-
cific PCR with the forward primer 5'-ATGGAGAGGAG-
GGGGCTGAGA-3' and the reverse primer 5'-
TGGATTTTGCCAATAATGTCCAGC-3' was used for rou-
tine genotyping for transgene status. Tail DNA of trans-
genic (TgDHCR7) mice produced a PCR product of 530
bp (data not shown). Southern blots of tail DNAs were
performed to identify three founder mice that harbored
the integrated transgene. For Southern analysis, 10 µg of
DNA was digested with Bam HI. The digested DNA was
separated on a 0.8% agarose gel, transferred to a Hybond-
N membrane, and hybridized with the 32P-labeled 1.5 kb
human DHCR7 cDNA. Expression levels of the human
DHCR7 transgene were determined by RT-PCR and West-
ern blot analyses, on tissues of offspring from positive
founders bred with C57BL/6J mice. Quantitative analyses
of transgene expression were performed by real-time PCR
(see below). Mice with high levels of transgene expression
in the liver were bred to C57BL/6J mice, and two inte-
grated transgenic lines, TgDHCR7-2  and  TgDHCR7-3,
were established. Both lines showed almost identical pat-
terns of transgene expression and were used interchange-
ably in all crosses. Dhcr7+/-  mice (N>12 on C57Bl/6J
background), described previously [14,27], were crossed
with  TgDHCR7  lines to generate Dhcr7+/- Tg+  animals.
These were subsequently intercrossed to obtain Dhcr7-/-
Tg+  mice. The transgenic mice were maintained as
hemizygotes by breeding with C57BL/6J mice (Jackson
Laboratories). All mice were housed in colony cages with
a 12-hour light/12-hour dark cycle and fed Teklad Mouse/
Rat Diet 7002 from Harlan Teklad (Madison, Wisconsin,
USA). For animal experiments, non-transgenic littermates
were used as controls for transgenic mice. All animal
experiments were performed with the approval of the
Institutional Animal Care and Research Advisory Com-
mittee at Medical College of Wisconsin.
Tissue expression of TgDHCR7
Total RNA was extracted from multiple tissues from post-
natal 10-day-old offspring or livers of embryos at E11.5,
E13.5, E16.5 from TgDHCR7  lines, as described previ-
ously [14,15]. Random hexamers were used as primers for
reverse transcription of 1 µg of total RNA, and cDNA first-
strand synthesis carried out using Thermoscript (Invitro-
gen) according to manufacturer's protocol. Specific
mRNA for TgDHCR7 was amplified using human DHCR7
cDNA primers (forward: 5'-GGACTGGTTTTCACT-
GGCGAGCG-3' and reverse: 5'-CCAGAGCAGGTGCGT-
GAGGAG-3'). The endogenous murine Dhcr7 and β-actin
were amplified using Dhcr7 cDNA primers (forward: 5'-
CCAAAGTCAAGAGTCCCAACGG-3' and reverse: 5'-
ACCAGAGGATGTGGGTAATGAGC-3') and the β-actin
gene primers, as described previously [15]. PCR amplifica-
tion was carried out as follows: denaturation for 3 min at
94°C and then a succession of 30 cycles by 30 sec at 94°C,
30 sec at 58°C, 1 min at 72°C, and a final extension at
72°C for 10 min. TgDHCR7 RT-PCR products (350 bp)
were gel-purified and sequenced to confirm it contained
correct spliced products using an automated capillary
sequencer (Beckman Coulter CEQ 8000, CA), as previ-
ously described [15]. SYBR-Green real-time PCR quantifi-
cation of transgene transcripts was performed with ABI
7300 Real-time PCR system, using human DHCR7 cDNA
primers (forward: 5'-CCCAGCTCTATACCTTGTGG-3' and
reverse: 5'-CCAGAGCAGGTGCGTGAGGAG-3'), murine
Dhcr7 cDNA primers (forward: GCCAAGACACCACCT-
GTGACAG-3' and reverse: 5'-TGGACGCCTCCCACAT-
AACC-3') and β-actin primers (forward:
ACCCTGTGCTGCTCACCGAG-3'and reverse: 5'-TGCCT-
GTGGTACGACCAGAGG-3'). Quantification of
TgDHCR7 mRNA levels in transgenic livers on E16.5, rel-
ative to endogenous murine Dhcr7 mRNA, was per-
formed using quantitative real-time PCR (qRT-PCR), with
normalization performed to the β-actin mRNA abun-
dance from the same sample.
For immunoblotting analysis of TgDHCR7, tissue mem-
brane fractions were extracted using ProteinExtract native
membrane protein extraction kit (Calbiochem, San
Diego, CA) according to manufacturer's protocol. Briefly,
approximately 50 mg of frozen tissues from brain, lung,
liver, spleen, kidney, or skeletal muscle was homogenized
in 2 ml of ice cold homogenate buffer added with cocktail
of protease inhibitors, using a tissue homogenizer (PRO
Scientific Inc., Oxford, CT) by three pulses of 10 seconds
each and then subjected to Dounce homogenizer, pestle
A, by 20 strokes. The homogenates were centrifuged at
16,000 g for 15 minutes at 4°C and supernatants referred
as to cytosolic fractions. The pellets were resuspended in
lysis buffer and gentled shaken for 30 minutes at 4°C, fol-
lowed by centrifugation at 16,000 g for 15 minutes at
4°C. The supernatants were collected and referred as to
membrane fractions. Protein concentrations in each
cytosolic and membrane fractions were determined using
Bio-Rad protein assay kit (Bio-Rad, Hercules, CA) and 40
µg of protein from each sample was separated by 8% SDS-
PAGE, transferred onto nitrocellulose membranes, incu-
bated with HA monoclonal antibody (1:400, Santa Cruz
Biotechnology, Santa Cruz, CA), Calnexin polyclonal
antibody (1:200, Santa Cruz Biotechnology), or caveolin-
1 (1:400, Santa Cruz Biotechnology) for 2 hours, followed
by HRP second antibodies (1:4000, Santa Cruz Biotech-
nology), and visualized by chemiluminescent detection
according to manufacturer's protocols (Perkin-Elmer Life
Sciences, Boston, MA).
Biochemical analyses
Sterol composition in tissues and plasma (pooled plasma
collected by decapitation from 9 animals, pooling per-
formed by combining plasma from 3 pups) were identi-BMC Developmental Biology 2007, 7:27 http://www.biomedcentral.com/1471-213X/7/27
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fied and quantitated by gas-chromatography-mass
spectrometry (GC-MS) as described previously [3].
Histology and immunohistochemistry
Timed pregnant females at embryonic day (E) 19.5 were
sacrificed. E19.5 fetuses were dissected free from the uteri
and thoracic body parts harvested, fixed in 10% neutral
buffered formalin, and embedded in paraffin. Tissues
from non-transgenic Dhcr7+/+  (WT),  Dhcr7-/-  Tg- and
Dhcr7-/- Tg+ animals were cut into 5-µm sections and
stained with hematoxylin-eosin for routine histological
examination. Immunohistochemistry (IHC) to determine
T1-α, SP-C, caveolin-1 (cav-1) and PECAM-1 expression
in tissue sections was performed in standard IHC proce-
dures as described previously [14]. Immunofluorescence
staining was performed to determine TgDHCR7 expres-
sion in livers by use of a monoclonal anti-HA probe con-
jugated with TRITC (1:200, Santa Cruz Biotechnology).
Isolation of detergent-resistant lipid rafts
A modification of the method of Mukherjee et al. [22] was
used to isolate lipid rafts from neonatal lung tissues.
Briefly, frozen lung tissues were homogenized in an ice-
cold lysis buffer containing 5% glycerol in buffer A (50
mM Tris-HCl, pH 8.0, 10 mM MgCl2, 0.15 M NaCl, 20
mM NaF, 1 mM Na3VO4, 5 mM β-mercaptoethanol, 10
µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM PMSF). Tissue
debris and nuclei were removed by centrifugation at 1,000
g for 5 minutes. Protein concentration of the postnuclear
supernatants (PNS) was measured using Protein Reagent
(Bio-Rad) and adjusted to 2 mg/ml. 10 % Triton X-100
(TX) was added to 2 ml of PNS to a final concentration of
0.5 % TX followed by a 30 min incubation on ice. The
samples were mixed with equal volume of 80 % (w/v)
sucrose in buffer A, and then overlaid with 2.0 ml each of
35, 30, 25, and 5 % (w/v) sucrose (all in buffer A). Sucrose
gradient was spun at 38,000 rpm in a Sorval 90 ultracen-
trifuge using TH-641 rotor for 15 hr at 4°C. Twelve frac-
tions of each 1.0 ml were collected from the top to
bottom. Sterol composition in each 12 fractions and
pooled lipid-raft and non-raft fractions was quantitatively
determined as described above and normalized to
organic-phosphate as determined by a phosphate assay
[38]. Based on cholesterol profile, as well as cellular
organelle protein markers and sphingolipid profile (data
not shown), lipid rafts or detergent resistant membranes
(DRMs) were defined as the membrane materials that
floated at the interface of 5% and 25% sucrose in the den-
sity range 1.055~1.115 g/ml (fraction 2~4); non-raft
materials were collected in the density range 1.130~1.180
g/ml (fraction 8~11).
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